64th Annual Scientific Session of the American College of Cardiology 2015
ACC 2015 More safety data with PCSK9 inhibitors: patients with very low LDL-C
Accumulating data with both alirocumab and evolocumab have so far not indicated specific safety issues. In the latest reports at ACC 2015, there were no safety signals in more than 5,000 patients who achieved very low low-density lipoprotein (LDL) cholesterol levels (<25 or <15 mg/dL)…
read more »
ACC 2015 Do the evolocumab 2-weekly and monthly regimens provide equivalent LDL-C lowering?
One of the questions clinicians often raise if whether the two dose regimens for evolocumab produce similar low-density lipoprotein (LDL) cholesterol lowering. This study answers this question showing clinical equivalence for changes in lipid parameters, including low-density lipoprotein (LDL) cholesterol, apolipoprotein B and lipoprotein(a). Data…
read more »
ACC 2015 Evolocumab effective in elderly patients; no safety issues
Treatment with the PCSK9 inhibitor evolocumab was effective in elderly patients (³65 years and ³75 years) with a side effect profile similar to placebo, according to the results of pooled analysis of nearly 2,000 patients from Phase 2, 3 and open-label studies. These findings specifically…
read more »
ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing
Results from the ODYSSEY CHOICE studies indicate flexibility in dosing with alirocumab, with 4-weekly regimens shown to be effective and well tolerated, according to Dr Michel Farnier, Point Medical, Dijon, France. Many patients at moderate to high cardiovascular (CV) risk and with poorly controlled hypercholesterolaemia…
read more »
ACC 2015: CASCADE FH: Unmet needs in education and care of familial hypercholesterolaemia
Baseline data from the CASCADE-FH Registry, presented at ACC 2015, highlight gaps in the care of patients with inherited high cholesterol – familial hypercholesterolaemia (FH). Only about 50% of patients understood the risks of their condition. Treatment was also suboptimal in nearly one-half of patients…
read more »
ACC 2015: What do the OSLER and ODYSSEY data really show? Expert analysis from Professor Derick Raal
March 15, 2015 At an eagerly anticipated hotline at ACC 2015, a pre-specified, exploratory analysis of the OSLER studies, showed that the PCSK9 monoclonal antibody evolocumab reduced low-density lipoprotein (LDL) cholesterol by 61%, and that this was associated with a 53% reduction in cardiovascular events…
read more »
